Successful Treatment of a Mixed Neuroendocrine-Nonneuroendocrine Neoplasm of the Colon with Metastases to the Thyroid Gland and Liver

Patients with mixed neuroendocrine-nonneuroendocrine neoplasms (MiNENs) of the colon have poor prognosis. Herein, we report a patient with MiNEN of the colon with metastases to the liver and the thyroid gland, with long-term survival. A 45-year-old man presented with anterior neck swelling. Histopathological examination of the thyroid tumor revealed neuroendocrine carcinoma (NEC), suggesting that a primary NEC in another organ had metastasized to the thyroid gland. Computed tomography to identify a primary NEC revealed two tumors: one in the liver and one in the transverse colon. A biopsy revealed that the histopathology of the liver and colon tumors was NEC and adenocarcinoma, respectively. Thereafter, the patient underwent surgical resection of the colon tumor and was finally diagnosed as colon MiNEN with metastases to the thyroid and liver. The surgical resection of the metastatic liver tumor was performed after several courses of systemic chemotherapy, and the patient survives presently without any recurrence for approximately seven years after the diagnosis. Surgical resection of each metastatic lesion combined with systematic chemotherapy apparently improved the prognosis of MiNEN of the colon with distant metastases

Conformationally-flexible and moderately electron-donating units-installed D–A–D triad enabling multicolor-changing mechanochromic luminescence, TADF and room-temperature phosphorescence

A novel twisted donor–acceptor–donor (D–A–D) π-conjugated compound that contains flexible and moderately-electron-donating units has been designed and synthesized. It exhibited not only multi-color-changing mechanochromic luminescence and thermally activated delayed fluorescence, but also, unexpectedly, room-temperature phosphorescence in a host layer

Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K‐RAS status for unresectable colorectal liver metastasis (BECK study): Long‐term results of survival

[Background/Purpose]To investigate the long‐term outcome and entire treatment course of patients with technically unresectable CRLM who underwent conversion hepatectomy and to examine factors associated with conversion to hepatectomy. [Methods]Recurrence and survival data with long‐term follow‐up were analyzed in the cohort of a multi‐institutional phase II trial for technically unresectable colorectal liver metastases (the BECK study). [Results]A total of 22/12 patients with K‐RAS wild‐type/mutant tumors were treated with mFOLFOX6 + cetuximab/bevacizumab. The conversion R0/1 hepatectomy rate was significantly higher in left‐sided primary tumors than in right‐sided tumors (75.0% vs 30.0%, P = .022). The median follow‐up was 72.6 months. The 5‐year overall survival (OS) rate in the entire cohort was 48.1%. In patients who underwent R0/1 hepatectomy (n = 21), the 5‐year RFS rate and OS rate were 19.1% and 66.3%, respectively. At the final follow‐up, seven patients had no evidence of disease, five were alive with disease, and 20 had died from their original cancer. All 16 patients who achieved 5‐year survival underwent conversion hepatectomy, and 11 of them underwent further resection for other recurrences (median: 2, range: 1‐4). [Conclusions]Conversion hepatectomy achieved a similar long‐term survival to the results of previous studies in initially resectable patients, although many of them experienced several post‐hepatectomy recurrences. Left‐sided primary was found to be the predictor for conversion hepatectomy

ラット小腸移植時における、冷・温阻血障害の指標としてのセロトニン測定の有用性の検討

京都大学0048新制・課程博士博士(医学)甲第8510号医博第2260号新制||医||743(附属図書館)UT51-2000-J19京都大学大学院医学研究科外科系専攻(主査)教授 千葉 勉, 教授 山岡 義生, 教授 田中 絋一学位規則第4条第1項該当Doctor of Medical ScienceKyoto UniversityDA

A Complete Response Case in a Patient with Multiple Lung Metastases of Rectal Cancer Treated with Bevacizumab plus XELIRI Therapy

It has been reported that many patients with lung metastasis of colorectal cancer (CRC) underwent chemotherapy with fluorouracil, folinic acid, oxaliplatin, irinotecan, or capecitabine. There is a small number of reports about the capecitabine and irinotecan (XELIRI) plus bevacizumab (BV) therapy for patients with metastatic CRC in Japan. We report a case of successful BV+XELIRI therapy for rectal cancer with multiple lung metastases as first-line chemotherapy. A 53-year-old female presented with advanced rectal cancer and metastatic lung tumors. Following surgery, the patient was treated with XELIRI+BV. After 6 courses, a computed tomography scan showed complete response of the lung metastases. No recurrence has occurred for 3 years after chemotherapy was stopped

Size selectivity of a trammel net for oval squid Sepioteuthis lessoniana

The size selectivity of a trammel net for herded oval squid Sepioteuthis lessoniana in Tateyama Bay, Chiba Prefecture, was estimated by comparison between the mantle length frequency distributions of oval squid caught by a trammel net and by a set net. The measured mesh sizes of the inner net of the trammel net and of the final section of the set net were 85.3 and 11.3 mm, respectively. In the trammel net fishery where oval squid are herded into the net, most of the oval squid are caught in the bag-shaped inner net. Hence, the logistic function was employed for the size selectivity curve of the trammel net. The ‘share each length's catch total’ (SELECT) model was implemented for the estimation of the selectivity curve. The size selectivity r(l) of the trammel net for the oval squid was expressed as a logistic function of the mantle length l: r(l)=exp (-18.57+0.88 l)/[1+exp (-18.57+0.88 l)]. From these logistic parameter estimates, the 50% selection mantle length and selection range (L75-L25) were calculated as 21.07 and 2.49 cm, respectively. The selection probability of oval squid whose mantle girth was equivalent to the mesh perimeter of the inner net was 0.09. Accordingly, oval squid of a girth smaller than the mesh perimeter were likely to pass through the mesh to escape from the net